Ania M Fiksinski1,2,3, Maude Schneider4,5, Janneke Zinkstok6, Danielle Baribeau7,8, Samuel J R A Chawner9,10, Jacob A S Vorstman6,7,8,11. 1. Department of Psychiatry, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands. A.M.Fiksinski@umcutrecht.nl. 2. Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, Canada. A.M.Fiksinski@umcutrecht.nl. 3. Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. A.M.Fiksinski@umcutrecht.nl. 4. Clinical Psychology Unit for Intellectual and Developmental Disabilities, Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland. 5. Department of Neurosciences, Center for Contextual Psychiatry, KU Leuven, Leuven, Belgium. 6. Department of Psychiatry, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands. 7. Department of Psychiatry, Hospital for Sick Children, Toronto, ON, Canada. 8. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 9. Cardiff University Centre for Human Developmental Science, School of Psychology, Cardiff University, Cardiff, UK. 10. MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK. 11. The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
Abstract
PURPOSE OF REVIEW: The 22q11.2 deletion syndrome (22q11DS) is associated with a broad spectrum of neurodevelopmental phenotypes and is the strongest known single genetic risk factor for schizophrenia. Compared to other rare structural pathogenic genetic variants, 22q11DS is relatively common and one of the most extensively studied. This review provides a state-of-the-art overview of current insights regarding associated neurodevelopmental phenotypes and potential implications for 22q11DS and beyond. RECENT FINDINGS: We will first discuss recent findings with respect to neurodevelopmental phenotypic expression associated with 22q11DS, including psychotic disorders, intellectual functioning, autism spectrum disorders, as well as their interactions. Second, we will address considerations that are important in interpreting these data and propose potential implications for both the clinical care for and the empirical study of individuals with 22q11DS. Third, we will highlight variable penetrance and pleiotropy with respect to neurodevelopmental phenotypes in 22q11DS. We will discuss how these phenomena are consistently observed in the context of virtually all rare pathogenic variants and that they pose substantial challenges from both a clinical and a research perspective. We outline how 22q11DS could be viewed as a genetic model for studying neurodevelopmental phenotypes. In addition, we propose that 22q11DS research can help elucidate mechanisms underlying variable expression and pleiotropy of neurodevelopmental phenotypes, insights that are likely relevant for 22q11DS and beyond, including for individuals with other rare pathogenic genetic variants and for individuals with idiopathic neurodevelopmental conditions.
PURPOSE OF REVIEW: The 22q11.2 deletion syndrome (22q11DS) is associated with a broad spectrum of neurodevelopmental phenotypes and is the strongest known single genetic risk factor for schizophrenia. Compared to other rare structural pathogenic genetic variants, 22q11DS is relatively common and one of the most extensively studied. This review provides a state-of-the-art overview of current insights regarding associated neurodevelopmental phenotypes and potential implications for 22q11DS and beyond. RECENT FINDINGS: We will first discuss recent findings with respect to neurodevelopmental phenotypic expression associated with 22q11DS, including psychotic disorders, intellectual functioning, autism spectrum disorders, as well as their interactions. Second, we will address considerations that are important in interpreting these data and propose potential implications for both the clinical care for and the empirical study of individuals with 22q11DS. Third, we will highlight variable penetrance and pleiotropy with respect to neurodevelopmental phenotypes in 22q11DS. We will discuss how these phenomena are consistently observed in the context of virtually all rare pathogenic variants and that they pose substantial challenges from both a clinical and a research perspective. We outline how 22q11DS could be viewed as a genetic model for studying neurodevelopmental phenotypes. In addition, we propose that 22q11DS research can help elucidate mechanisms underlying variable expression and pleiotropy of neurodevelopmental phenotypes, insights that are likely relevant for 22q11DS and beyond, including for individuals with other rare pathogenic genetic variants and for individuals with idiopathic neurodevelopmental conditions.
Authors: Maude Schneider; Marco Armando; Frauke Schultze-Lutter; Maria Pontillo; Stefano Vicari; Martin Debbané; Stephan Eliez Journal: Schizophr Res Date: 2018-11-07 Impact factor: 4.939
Authors: Ania M Fiksinski; Maude Schneider; Clodagh M Murphy; Marco Armando; Stefano Vicari; Jaume M Canyelles; Doron Gothelf; Stephan Eliez; Elemi J Breetvelt; Celso Arango; Jacob A S Vorstman Journal: Am J Med Genet A Date: 2018-09-08 Impact factor: 2.802
Authors: Anne S Bassett; Chelsea Lowther; Daniele Merico; Gregory Costain; Eva W C Chow; Therese van Amelsvoort; Donna McDonald-McGinn; Raquel E Gur; Ann Swillen; Marianne Van den Bree; Kieran Murphy; Doron Gothelf; Carrie E Bearden; Stephan Eliez; Wendy Kates; Nicole Philip; Vandana Sashi; Linda Campbell; Jacob Vorstman; Joseph Cubells; Gabriela M Repetto; Tony Simon; Erik Boot; Tracy Heung; Rens Evers; Claudia Vingerhoets; Esther van Duin; Elaine Zackai; Elfi Vergaelen; Koen Devriendt; Joris R Vermeesch; Michael Owen; Clodagh Murphy; Elena Michaelovosky; Leila Kushan; Maude Schneider; Wanda Fremont; Tiffany Busa; Stephen Hooper; Kathryn McCabe; Sasja Duijff; Karin Isaev; Giovanna Pellecchia; John Wei; Matthew J Gazzellone; Stephen W Scherer; Beverly S Emanuel; Tingwei Guo; Bernice E Morrow; Christian R Marshall Journal: Am J Psychiatry Date: 2017-07-28 Impact factor: 18.112
Authors: Sungkun Chun; Joby J Westmoreland; Ildar T Bayazitov; Donnie Eddins; Amar K Pani; Richard J Smeyne; Jing Yu; Jay A Blundon; Stanislav S Zakharenko Journal: Science Date: 2014-06-06 Impact factor: 47.728
Authors: Jennifer L Cohen; Terrence B Crowley; Daniel E McGinn; Carey McDougall; Marta Unolt; Michele P Lambert; Beverly S Emanuel; Elaine H Zackai; Donna M McDonald-McGinn Journal: Am J Med Genet A Date: 2018-09-23 Impact factor: 2.802
Authors: Mari E K Niemi; Hilary C Martin; Daniel L Rice; Giuseppe Gallone; Scott Gordon; Martin Kelemen; Kerrie McAloney; Jeremy McRae; Elizabeth J Radford; Sui Yu; Jozef Gecz; Nicholas G Martin; Caroline F Wright; David R Fitzpatrick; Helen V Firth; Matthew E Hurles; Jeffrey C Barrett Journal: Nature Date: 2018-09-26 Impact factor: 49.962
Authors: Samuel J R A Chawner; Michael J Owen; Peter Holmans; F Lucy Raymond; David Skuse; Jeremy Hall; Marianne B M van den Bree Journal: Lancet Psychiatry Date: 2019-05-02 Impact factor: 77.056
Authors: Jennifer Cable; Ryan H Purcell; Elise Robinson; Jacob A S Vorstman; Wendy K Chung; John N Constantino; Stephan J Sanders; Mustafa Sahin; Ricardo E Dolmetsch; Bina Maniar Shah; Audrey Thurm; Christa L Martin; Carrie E Bearden; Jennifer G Mulle Journal: Ann N Y Acad Sci Date: 2021-08-02 Impact factor: 6.499